These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 28045951

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W, Wu QD, Zhang M, Kong YL, Cao PR, Zheng W, Xu JH, Ye M.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):862-71. PubMed ID: 25449780
    [Abstract] [Full Text] [Related]

  • 24. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
    Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL.
    Cancer Res; 2013 Oct 01; 73(19):6013-23. PubMed ID: 23918797
    [Abstract] [Full Text] [Related]

  • 25. Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
    Jia X, Cheng J, Shen Z, Shao Z, Liu G.
    Mol Med Rep; 2018 Apr 01; 17(4):5470-5476. PubMed ID: 29393454
    [Abstract] [Full Text] [Related]

  • 26. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T, Yamamoto H, Kanzaki H, Suzawa K, Yoshioka T, Tomida S, Cui X, Murali R, Namba K, Sato H, Torigoe H, Watanabe M, Shien K, Soh J, Asano H, Tsukuda K, Kitamura Y, Miyoshi S, Sendo T, Toyooka S.
    PLoS One; 2017 Apr 01; 12(2):e0171356. PubMed ID: 28158234
    [Abstract] [Full Text] [Related]

  • 27. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
    Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ.
    Cancer Res; 2006 Feb 01; 66(3):1630-9. PubMed ID: 16452222
    [Abstract] [Full Text] [Related]

  • 28. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 29. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA, Vellon L, Lupu R.
    Ann Oncol; 2005 Aug 15; 16(8):1253-67. PubMed ID: 15870086
    [Abstract] [Full Text] [Related]

  • 30. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC.
    Int J Oncol; 2007 Feb 15; 30(2):509-20. PubMed ID: 17203234
    [Abstract] [Full Text] [Related]

  • 31. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT, Metz MZ, Kane SE.
    Breast Cancer Res Treat; 2005 May 15; 91(2):187-201. PubMed ID: 15868447
    [Abstract] [Full Text] [Related]

  • 32. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
    O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ.
    Clin Cancer Res; 2014 Jul 01; 20(13):3507-20. PubMed ID: 24879796
    [Abstract] [Full Text] [Related]

  • 33. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
    Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ, de Cremoux P, Stenvang J, Lykkesfeldt AE.
    Breast Cancer Res Treat; 2009 Mar 01; 114(2):263-75. PubMed ID: 18409071
    [Abstract] [Full Text] [Related]

  • 34. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
    Naderi A, Chia KM, Liu J.
    Breast Cancer Res; 2011 Apr 01; 13(2):R36. PubMed ID: 21457548
    [Abstract] [Full Text] [Related]

  • 35. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
    Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J, Rosen N.
    Oncogene; 2010 Jan 21; 29(3):325-34. PubMed ID: 19855434
    [Abstract] [Full Text] [Related]

  • 36. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines.
    Emlet DR, Brown KA, Kociban DL, Pollice AA, Smith CA, Ong BB, Shackney SE.
    Mol Cancer Ther; 2007 Oct 21; 6(10):2664-74. PubMed ID: 17938260
    [Abstract] [Full Text] [Related]

  • 37. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
    Wang Q, Zhang X, Shen E, Gao J, Cao F, Wang X, Li Y, Tian T, Wang J, Chen Z, Wang J, Shen L.
    Cancer Lett; 2016 Sep 28; 380(1):20-30. PubMed ID: 27317872
    [Abstract] [Full Text] [Related]

  • 38. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.
    Eur J Cancer; 2014 Oct 28; 50(15):2725-34. PubMed ID: 25128455
    [Abstract] [Full Text] [Related]

  • 39. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
    Portman N, Milioli HH, Alexandrou S, Coulson R, Yong A, Fernandez KJ, Chia KM, Halilovic E, Segara D, Parker A, Haupt S, Haupt Y, Tilley WD, Swarbrick A, Caldon CE, Lim E.
    Breast Cancer Res; 2020 Aug 12; 22(1):87. PubMed ID: 32787886
    [Abstract] [Full Text] [Related]

  • 40. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.
    Breast Cancer Res; 2014 Sep 11; 16(5):430. PubMed ID: 25212826
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.